Results 71 to 80 of about 49,135 (301)

Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke

Stroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— Patients with transient ischemic attack (TIA) and minor ischemic stroke are at risk for early recurrent cerebral ischemia.
K. Butcher, K. Ng, P. Sheridan, Thalia Shoshana Field, S. Coutts, M. Siddiqui, L. Gioia, B. Buck, M. Hill, Jodi Miller, A. Klahr, L. Sivakumar, O. Benavente, R. Hart, Mike Sharma   +14 more
semanticscholar   +1 more source

Neck‐vein thrombosis during spaceflight

British Journal of Clinical Pharmacology, EarlyView.
Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley   +1 more source

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations

Clinical and Applied Thrombosis/Hemostasis, 2019
To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj   +1 more source

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson, Annemans, Arya, Barco, Bischof, Bjorvatn, Botteman, Braidy, Brockbank, Capri, Caprini, Cohoon, Curtis, Dahl, Dahl, Davies, Diamantopoulos, Dranitsaris, Dranitsaris, Ende-Verhaar, Gomez-Outes, Gordois, Gould, Haentjens, Hamidi, Hauck, Heit, Husereau, Jameson, Jameson, Kahn, Kapoor, Lundkvist, McCullagh, McCullagh, McDonald, Migliaccio-Walle, Postma, Quinlan, Reeves, Revankar, Riemsma, Roberts, Ryttberg, Sterne, Stevenson, Wade, Wang, Warwick, White, Wille-Jørgensen, Wolowacz, Wolowacz, Zindel   +53 more
core   +4 more sources

The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation

British Journal of Clinical Pharmacology, 2020
Our study aimed to determine the impact of genetic polymorphisms of ABCB1 and CES1 on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran in patients with nonvalvular atrial fibrillation (NVAF).
Qiuyi Ji, Chunyu Zhang, Qing Xu, Z. Wang, Xiaoye Li, Qian-zhou Lv   +5 more
semanticscholar   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease

Case Reports in Medicine, 2013
Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim, Mrinal Yadava, In Chul An, Abrar Sayeed, Heather S. Laird-Fick, Venu Gourineni, George S. Abela   +6 more
doaj   +1 more source

New oral anticoagulants and their reversal agents [PDF]

, 2018
Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana, Diaconu, Camelia C, Laslo, Crista L, Marcu, Dragos, Neagu, Tiberiu P, Paduraru, Dan N, Pantea Stoian, Anca, Socea, Bogdan, Socea, Laura I, Stanescu, Ana Maria Alexandra   +9 more
core   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Рациональная фармакотерапия в кардиологии, 2016
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj   +1 more source